Skip to main content
Porträt Susanna Hofmann
Helmholtz Munich | ©Petra Nehmeyer
+49 89 3187 2112E-MailGebäude/Raum: Campus Neuherberg, building 3620, room 306b

Prof. Susanna Hofmann, MD

Head of the Independent Research Group "Women and Diabetes" , Institute of Diabetes and Regeneration Research (IDR) and W2 Professor of Lipid Metabolism and Metabolic Diseases at the Medical Faculty of the Ludwig Maximilians University Munich (LMU)

“Patients and particularly women with diabetes develop cardiovascular disease with substantial loss of life expectancy. Our mission is to investigate the molecular mechanisms causing sex specific differences in diabetic cardiovascular disease "

Prof. Susanna Hofmann, MD

Head of the Independent Research Group "Women and Diabetes" , Institute of Diabetes and Regeneration Research (IDR) and W2 Professor of Lipid Metabolism and Metabolic Diseases at the Medical Faculty of the Ludwig Maximilians University Munich (LMU)

“Patients and particularly women with diabetes develop cardiovascular disease with substantial loss of life expectancy. Our mission is to investigate the molecular mechanisms causing sex specific differences in diabetic cardiovascular disease "

Research Focus and Academic Career

Univ.-Prof. Dr. med. Susanna Hofmann is a Physician Scientist, W2 Professor of Lipid Metabolism and Metabolic Diseases at the Medical Faculty of the Ludwig Maximilians University Munich (LMU) and Head of the Independent Research Group "Women and Diabetes" at Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU).

After her studies at the University of Padua and the Free University of Berlin, she completed her doctoral thesis with Summa cum Laude and worked as a resident at the Medical Clinic of the LMU. Subsequently, she joined the Division of Experimental Diabetes, Mount Sinai School of Medicine, New York, as a postdoctoral fellow with an Emmy Noether fellowship from the German Research Foundation (DFG) to study cardiovascular complications in diabetes. After a long research stay in the USA, she moved back to Munich in 2011.

The focus of her research is on gender differences in cardio-metabolic disease and the development of personalized therapeutic approaches. At LMU, she teaches the course: "Gender Medicine: Gender Aspects in Endocrinology and Diabetology" in the clinical section of the medical faculty. She is a board member of the DFG funded SFB1123 and a member of the faculty council. In addition to her reviewing activities for numerous high-ranking biomedical journals and European research funding agencies (EU Horizon 2020, FWO, La Caixa), she is Co-Editor In Chief of the journal Frontiers in Endocrinology Section Clinical Diabetes since 2020. Since 2018, she has been a board member of the German Society of Gender Medicine and has contributed to the establishment of a European Gender Health Network and a strategy for the implementation of sex and gender aspects in biomedicine and health research through her participation in the European Gender Medicine Project (EUGenMed).

Expertise

DiabetesObesityDyslipidemiaCardiovascular disease

Professional Career

Since 2021

Vice chair of the German Society for Gender Medicine (DGesGM)

Medical Faculty Council Member of LMU

Since 2014

W2 Professor for Lipid Metabolism and Metabolic Disease, LMU

since 2011

Division Head, “Women and Diabetes”, Helmholtz Zentrum Munich

Honors and Awards

  • 2011
    Irvine H. Page Young Investigator Research Award by the Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) of the American Heart Association (AHA)

  • 2010
    BIRCWH Research Scholar Award sponsored by the NIH Office of Research on Women’s Health (ORWH)

  • 2000
    Emmy Noether Research Fellowship Award of the German Research Council (DFG)

Gold Star Awards Luxury Background
suppa - stock.adobe.com

Most important Publications

See all

2023 Diabetologia

Lutter D, Sachs S, Walter M, Kerege A, Perreault L, Kahn DE, Wolide AD, Kleinert M, Bergman BC, Hofmann SM

Skeletal muscle and intermuscular adipose tissue gene expression profiling identifies new biomarkers with prognostic significance for insulin resistance progression and intervention response

Aims/hypothesis Although insulin resistance often leads to type 2 diabetes mellitus, its early stages are often unrecognised, thus reducing the probability of successful prevention and intervention. Moreover, treatment efficacy is affected by the genetics of the individual. We used gene expression profiles from a cross-sectional study to identify potential candidate genes for the prediction of diabetes risk and intervention response. Methods Using a multivariate regression model, we linked gene expression profiles of human skeletal muscle and intermuscular adipose tissue (IMAT) to fasting glucose levels and glucose infusion rate. Based on the expression patterns of the top predictive genes, we characterised and compared individual gene expression with clinical classifications using k-nearest neighbour clustering. The predictive potential of the candidate genes identified was validated using muscle gene expression data from a longitudinal intervention study. Results We found that genes with a strong association with clinical measures clustered into three distinct expression patterns. Their predictive values for insulin resistance varied substantially between skeletal muscle and IMAT. Moreover, we discovered that individual gene expression-based classifications may differ from classifications based predominantly on clinical variables, indicating that participant stratification may be imprecise if only clinical variables are used for classification. Of the 15 top candidate genes, ST3GAL2, AASS, ARF1 and the transcription factor SIN3A are novel candidates for predicting a refined diabetes risk and intervention response. Conclusion/interpretation Our results confirm that disease progression and successful intervention depend on individual gene expression states. We anticipate that our findings may lead to a better understanding and prediction of individual diabetes risk and may help to develop individualised intervention strategies.

2023 Cell Metabolism

Becker M, Joseph SS, Garcia-Carrizo F, Tom RZ, Opaleva D, Serr I, Tschöp MH, Schulz TJ, Hofmann SM, Daniel C

Regulatory T cells require IL6 receptor alpha signaling to control skeletal muscle function and regeneration

Muscle-residing regulatory T cells (Tregs) control local tissue integrity and function. However, the molecular interface connecting Treg-based regulation with muscle function and regeneration remains largely unexplored. Here, we show that exercise fosters a stable induction of highly functional muscle-residing Tregs with increased expression of amphiregulin (Areg), EGFR, and ST2. Mechanistically, we find that mice lacking IL6Rα on T cells (TKO) harbor significant reductions in muscle Treg functionality and satellite and fibro-adipogenic progenitor cells, which are required for muscle regeneration. Using exercise and sarcopenia models, IL6Rα TKO mice demonstrate deficits in Tregs, their functional maturation, and a more pronounced decline in muscle mass. Muscle injury models indicate that IL6Rα TKO mice have significant disabilities in muscle regeneration. Treg gain of function restores impaired muscle repair in IL6Rα TKO mice. Of note, pharmacological IL6R blockade in WT mice phenocopies deficits in muscle function identified in IL6Rα TKO mice, thereby highlighting the clinical implications of the findings.